您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 骨科药物->肌肉骨骼及关节障碍
处方药:处方药
包装规格: 10毫克/10毫升/瓶
计价单位:
  点击放大  
生产厂家英文名:
Avadel Legacy Pharmaceuticals, LLC
该药品相关信息网址1:
http://www.bloxiverz.com/
原产地英文商品名:
Bloxiverz 10mg/10ml vial
原产地英文药品名:
NEOSTIGMINE METHYLSULFATE
中文参考商品译名:
Bloxiverz 10毫克/10毫升/瓶
中文参考药品译名:
甲硫酸新斯的明
原产地国家批准上市年份:
2013/07/24
英文适应病症1:
Used after surgery to reverse non-depolarizing neuromuscular blocker effects
临床试验期:
完成
中文适应病症参考翻译1:
用于手术后逆转非去极化型神经肌肉阻滞剂的效应
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(202122418162732.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文甲硫酸新斯的明处方资料(仅供参考)

Flamel Technologies公司宣布,美国食品药品管理局(FDA)已批准Bloxiverz(甲硫酸新斯的明)用于手术后逆转非去极化型神经肌肉阻滞剂的效应。这种药物为静脉应用,将有0.5和1.0 mg/ml两种规格可供选择。

Bloxiverz是一种胆碱酯酶抑制剂,通过在胆碱能神经冲动传导部位与乙酰胆碱酯酶竞争性结合而抑制胆碱酯酶的水解。该药物通过促进神经肌肉接头处的冲动传导而提高胆碱能神经活性。新斯的明增高突触乙酰胆碱水平的能力是其有效逆转神经肌肉阻滞效应的基础。新斯的明不易穿透血脑屏障,因此不会对中枢神经系统的胆碱能神经活性产生显著影响。

治疗中最常见的不良反应包括心动过缓、恶心和呕吐。为了降低心动过缓风险,在使用Bloxiverz之前应使用阿托品或格隆溴铵。Bloxiverz应慎用于有心律失常、近期急性冠脉综合征、迷走神经紧张、甲状腺功能亢进、重症肌无力、癫痫或消化性溃疡患者。因为偶有患者发生过敏,故在使用时应备好阿托品和抗过敏药物。当神经肌肉阻滞很轻微时,使用大剂量Bloxiverz可能导致神经肌肉功能障碍。当接近完全从神经肌肉阻滞状况中恢复时,应减少Bloxiverz的剂量。


Efficacy

There is no confirmation that unapproved drugs are effective or deliver the active ingredient/s in their labeled amount and timeframe. Bloxiverz has been reviewed and approved by the FDA so that you can be assured that the product will perform as intended.


INDICATIONS AND USAGE

BLOXIVERZ, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery in adults and pediatric patients of all ages.


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BLOXIVERZ is contraindicated in patients with known hypersensitivity to neostigmine. It is also contraindicated in patients with peritonitis or mechanical obstruction of the intestinal or urinary tract.


WARNINGS AND PRECAUTIONS

Atropine or glycopyrrolate should be administered prior to BLOXIVERZ to minimize risk of bradycardia.

BLOXIVERZ should be used with caution in patients with the following coexisting conditions as serious reactions may occur: coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome or myasthenia gravis.

Neuromuscular dysfunction can occur if large doses of BLOXIVERZ are administered when neuromuscular blockade is minimal; reduce dose if recovery from neuromuscular blockade is nearly complete.


ADVERSE REACTIONS

The most common adverse reactions during treatment are bradycardia, nausea and vomiting.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(202122418162732.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2021-2-25
附件:
202122418162732.pdf    



 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com